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Design of evidence based initiative: 2 components
1. OUD MAT educational module 2. MAT protocol initiation/implementation
1. MAT educational module: Pre/post test, MAT educational module/PPT via electronic learning 
system (online NET learning)
• 10 multiple choice questions (pre/post test)
• Program evaluation by experts
2. MAT Protocol initiation/implementation: screening (NIDA (universal screening), COWS 
(withdrawal)), Treatment with Buprenorphine, naloxone), Overdose education, Naloxone kit 
distribution, Discharge Referral to MAT clinic 
• US opioid epidemic = public health emergency
• 1999-2018 -> 450,000< Overdose deaths
• 2.4 million in US suffer from OUD
• 20% deaths of 24-25y involved opioids
• Opioid epidemic strongly impacts EDs nationwide
• 30% increase in OUD ED visits from 2016-2017, continues to surge
Research Evidence indicates ED is an opportunity to save more lives
• Pts with overdose likely to suffer more overdose, be seen in the ED as an 
opportunity for action
• Strong evidence of improved outcomes with ED MAT initiation
• ED is a frontline access to the hospital, primary access to health care for 
most if not all OUD pts
• Repeat overdose visits prevented/reduced with early MAT initiation in ED 
• Screening is necessary to identify and care for ED patients with OUD
• With universal screening and early MAT initiation, ED can improve care 
and outcomes for OUD patients
• ED can provide education, initiate MAT, supply naloxone kits, link patients 
to long term treatment, direct patients to ultimate recovery
• But many EDs are not playing their part in this process 
To improve patient quality and outcome by 
developing, delivering and evaluating a 
MAT education program, early initiation 
and implementation of MAT protocol within 
the Mount Sinai Hospital ED and reviewing 
documentation data for protocol adherence
• ED providers are currently on the front line of the opioid crisis
• ED is the initial access for opioid dependent patients seeking medical care
• OUD universal screening, education, treatment and management identify and 
treat those who may otherwise be undetected until 
withdrawal/overdose/death are more evident
• ED providers (MDs and APPs) and nurses play a pivotal role in early recognition 
of OUD patients, early initiation of MAT to relieve withdrawal symptoms and 
decrease craving to reduce repeat abuse and referral to ongoing MAT treatment 
anticipating for an ultimate recovery
• EDs will continue to serve as front line access for patients with OUD/overdose
• U.S. declares the opioid overdose as an epidemic and as a public health 
emergency calling for an urgent need for early treatment and active 
commitment from the emergency medicine community
• This project will enable emergency providers and nurses to manage OUD with 
the evidence based approach and efficiently transition care to long term 
referral services aiming for an ultimate recovery
• This project will help turn the tide against this opioid epidemic and improve 
quality of life for all
Results
Project implementation and data collection currently in progress and results are 
pending
Currently in progress:
• Feb, 2021- Implementation 
• Naloxone kit distribution/education at discharge
• MAT referral order created in ED EHR
• Limited Buprenorphine initiation in ED
• March, 2021-Nursing education on 
• Triage EHR revision to include universal screening questions 
• Pretest/post test for PPT module
• ED MAT protocol/buprenorphine initiation, MAT referral PPT 
module via online NET learning
• Further project implementation and data collection will include analysis of 
number of Buprenorphine initiation, MAT referral orders and Naloxone kit 
distribution and documentation of each
1. Educate , 2. Initiate/implement MAT protocol (Screen, initiate Buprenorphine 
TX, discharge with Naloxone kit and provide referral to MAT clinic) and 3. evaluate 
on staff adherence
Project Implementation
Ethics/Human Subjects Protection: IRB exempted by Mount Sinai Hospital and Loyola 
University Chicago
Project type: Quality Improvement initiative to implement ED MAT educational 
module, screening, initiation and referral. To evaluate for adherence to EHR MAT 
protocol and documentation
Setting: Mount Sinai ED – level 1 Adult Trauma center, non-profit safety net hospital in 
SW Chicago, treats 50,000< underserved patients yearly, consisting significant 
OUD/overdose patients. 288 acute care beds, teaching hospital training 700< 
healthcare professionals yearly
Practice Gap Analysis: No existing OUD screening or treatment protocol 
Key Stakeholder & Resources: ED/Nursing directors, IT, pharmacists, educators etc.
Participants/Sample: Convenience sample: ED providers (MDs, APPs, RNs) working at 
MSH ED (excludes Holy cross providers) and ED patients 18y< , screened as OUD 
patients (risk for overdose/withdrawal), clinically indicated for MAT
Project Objectives: 
1)Revise the Electronic Health Record (EHR) system to include:
-NIDA quick Screen; COWS tool utilization
-OUD MAT Protocol (Buprenorphine initiation, Naloxone kit distribution, MAT 
referral)
2) Develop and implement an OUD educational module and link to DEA X-waiver 
training for ED APPs if needed (X waiver no longer required for MDs as of Jan 2021 by 
HHS)
3) Evaluate learning outcomes via pretest/posttest and program end evaluation
4) Evaluate EHR documentation
-NIDA & COWS screening documentation for staff completeness and accuracy
-Early initiation and administration of buprenorphine when clinically indicated
-Naloxone kit distribution and education with discharge instruction
-Referral to MAT clinic
Sources of Data:
• Triage NIDA screening tool, positive screens
• 10 questions pre/post educational module questions reviewed by experts for 
content validity
• 5 questions Likert scale survey rating achievement of objectives
• EHR documentation: 
• Number of naloxone kit distributions and MAT referrals by ED nurses 
• Number of ED Buprenorphine initiation/administrations by providers 
and Nurses
Budget: Patient Naloxone kit education pamphlets (Free), online modules (Free)
Project 2021 Proposed Timeline:
• Feb: Discharge Naloxone distribution; March/April: EHR Revision, Education, 
limited MAT initiation, MAT referral; April/May: Full MAT initiation in ED, Full MAT 
referral; June: Data collection/evaluation, June/July: Results Dissemination
Improve patient survivalImprove
Increase retention in treatmentIncrease
Decrease illicit opiate use/criminal activityDecrease
Improve birth outcomes among pregnant women with OUD Improve
Increase ability to gain/maintain employmentIncrease
Method
JAMA study tested and compared the efficacy of 3 interventions for opioid 
dependence in ED: 1. screening and referral to treatment, 2. screening, brief 
intervention and referral to treatment, 3. screening, brief intervention, ED 
treatment with Buprenorphine/naloxone and referral to treatment through 
randomized clinical trial LEVEL I, High Quality 
• ED initiated Buprenorphine treatment group had the highest engagement in 
addiction treatment, reported reduction of illicit opioid use and decreased use 
of inpatient addiction treatment services 
• ED initiated Buprenorphine treatment group was twice as likely to be engaged 
in addiction treatment and more likely to stay in treatment
• Replication in other EDs recommended for widespread adoption
Annals of Emergency Medicine, Toxicology study reported short term and 1 yr 
mortality of nonfatal opioid overdose patients treated/released from ED remains 
high
• First month, particularly the first 2 days after overdose is the highest risk period
• Overdose survivor is at high risk, should receive Buprenorphine, counseling and 
referral to Buprenorphine treatment before ED discharge ED initiated 
Buprenorphine prevents relapsing into high risk illicit drug use Level III, High 
Quality
BMC studied baseline craving with craving after Buprenorphine treatment
• Craving decreased with high dose of Buprenorphine treatment group with 
greatest reduction. A single, high dose of Buprenorphine reduces withdrawals 
Level I, High quality 
